Mercado mundial de medicamentos para trastornos neurológicos: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado                              

A nivel mundial, los trastornos neurológicos son la principal causa de muerte. Se definen como trastornos del sistema nervioso central y periférico. Las enfermedades afectan principalmente a la población de edad avanzada. Puede progresar y requerir un tratamiento a largo plazo. Las anomalías neurológicas congénitas aparecen durante las primeras etapas del desarrollo embrionario y pueden detectarse al nacer. Una variedad de factores, como lesiones cerebrales traumáticas, problemas inmunológicos, inyecciones posnatales, lesiones de la médula espinal, neoplasia y exposición a sustancias químicas ambientales o venenos, pueden causar trastornos neurológicos adquiridos después del nacimiento. Muchas enfermedades bacterianas, virales, fúngicas y parasitarias pueden dañar el sistema nervioso, lo que resulta en enfermedades neurológicas.

Data Bridge Market Research analiza que el mercado de medicamentos para trastornos neurológicos se valoró en USD 79,40 mil millones en 2021 y se espera que alcance los USD 125,60 mil millones para 2029, registrando una CAGR del 5,9% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Definición de mercado

Una enfermedad neurológica se produce cuando alguna parte del cerebro o del sistema nervioso funciona mal, lo que provoca síntomas físicos y/o psicológicos. Los trastornos neurológicos se tratan con una variedad de medicamentos, incluidos antipsicóticos, antiepilépticos, anticolinérgicos y analgésicos. Además, el medicamento que se prescribe depende principalmente de la condición neurológica del paciente. Estos medicamentos ayudan a controlar las afecciones neurológicas, a reducir los síntomas y a mejorar la calidad de vida. Los corticosteroides, que se utilizan ampliamente para tratar la esclerosis múltiple y ayudan a reducir la inflamación, se encuentran entre los medicamentos neurológicos más utilizados.

Dinámica del mercado de medicamentos para trastornos neurológicos

Conductores

• Creciente población geriátrica

El crecimiento del mercado se ve impulsado por un aumento de la población geriátrica, que conduce a la presentación de numerosos problemas neurológicos. Los trastornos cerebrovasculares, como el accidente cerebrovascular y la migraña, afectan a personas de todas las edades en países como Alemania, el Reino Unido e Italia. En adultos de 45 a 84 años, Francia, Suecia, Grecia, Dinamarca y Rusia tienen altas tasas de enfermedad cerebrovascular. Según un estudio publicado en el NCBI en 2018, la prevalencia de accidente cerebrovascular en Singapur fue del 7,67 por ciento entre las personas de 65 años o más.

• Aumentar la inversión en infraestructura sanitaria

Otro factor importante que influye en la tasa de crecimiento del mercado de la dermatitis es el aumento del gasto sanitario, que ayuda a mejorar su infraestructura. Además, varias organizaciones gubernamentales tienen como objetivo mejorar la infraestructura sanitaria aumentando la financiación, lo que influirá aún más en la dinámica del mercado.

• Aumentar la concienciación sobre el diagnóstico precoz de enfermedades

The neurological disorder drugs market is expected to grow due to rising awareness associated with early disease diagnosis through awareness campaigns by government regulatory bodies and private organizations, and market entry of efficient drugs in the near future, owing to the presence of a strong drug pipeline. As per a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA) in April 2018, biopharmaceutical companies in the United States are currently developing 537 medications for various neurological illnesses. 95 drugs for brain tumors, 46 for chronic pain, and 92 for Alzheimer's disease are among them. Multiple sclerosis, migraines, amyotrophic lateral sclerosis, and Parkinson's disease are among the 30 illnesses being researched.

Furthermore, surging number of government initiatives to spread awareness and increasing prevalence of neurological diseases such as dementia will result in the expansion of neurological disorder drugs market. Along with this, sedentary lifestyle of people and will enhance the growth rate of the market.

Opportunities

• Development of new drugs   

Moreover, the market's growth is fueled by an increase in the development of new drugs. This will provide beneficial opportunities for the market growth. Brain injuries and neurological disorders are among the major causes of death around the world. As a result, researchers are pursuing chances to produce new medications that could improve the treatment of neurological disorders by altering glucose metabolism. For instance, Gero Discovery, a provider of novel therapeutic alternatives for neurodegenerative disorders, recently revealed the discovery of a prospective medicine that uses the technique of glucose metabolism alteration in stressed neurons to assist avoid neuronal death. To create novel treatments, companies in the neurological disorder drugs industry need work with qualified researchers.

• Increase in the number of research and development activities       

The increase in the number of research and development activities is estimated to provide various beneficial opportunities for the neurological disorder drugs market’s growth. New therapeutic techniques for the treatment of Parkinson's disease are being adopted by companies in the neurological disorder pharmaceuticals market. This leads to high number of research activities to better understand the disease's genetic risk factors in order to find better drugs. As a result, mutations in the GBA1 gene are emerging as a prospective therapeutic development strategy. Mutations in the gene, however, may cause GCase (glucocerebrosidase) enzyme deficiencies. As a result, manufacturers in the neurological disorder pharmaceuticals market are concentrating on activating wild type GCase in order to produce new therapeutic molecules for the treatment of Parkinson's disease.

Moreover, the market's growth is fueled by rising investment for the development of advanced technologies and increase in the number of emerging markets. These factors will provide beneficial opportunities for the neurological disorder drugs market growth.

Restraints/Challenges

On the other hand, high cost associated with the research and development activities will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the neurological disorder drugs market. Additionally, product recalls and strict government regulations will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This neurological disorder drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neurological disorder drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Neurological disorder drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Recent Development

• In September 2021, Sumitomo Dainippon Pharma and Otsuka had announced a collaboration as well as license agreement for four psychiatry and neurology compounds namely ulotaront (SEP-363856), SEP-4199, SEP-378614, and SEP-380135. Under the terms of the partnership, Sunovion and Otsuka will split the costs and revenues of clinical trials, regulatory applications, and commercialization in each of these nations and areas. Additional ulotaront indications, and also SEP-378614 and SEP-380135 indications, will be identified after future Sumitomo Dainippon Pharma Group and Otsuka consultations.

Global Neurological Disorder Drugs Market Scope

The neurological disorder drugs market is segmented on the basis of indication, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Epilepsy
• Alzheimer’s Disease
• Parkinson’s Disease
• Multiple Sclerosis
• Cerebrovascular Disease
• Others

Drug Class

• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Antiepileptic
• Antipsychotic and Antidepressant
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Neurological Disorder Drugs Market Regional Analysis/Insights

The neurological disorder drugs market is analysed and market size insights and trends are provided by country, indication, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the neurological disorder drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the neurological disorder drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of prevalence of neurological disorder and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players and increase in number of FDA approval drugs will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to high presence of generic manufacturer in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Neurological Disorder Drugs Market Share Analysis

El panorama competitivo del mercado de medicamentos para trastornos neurológicos proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de medicamentos para trastornos neurológicos.

Algunos de los principales actores que operan en el mercado de medicamentos para trastornos neurológicos son:

• Merck KGaA (Alemania)
• Eisai Co., Ltd. (Japón)
• AstraZeneca (Reino Unido)
• Sanofi (Francia)
• Novartis AG (Suiza)
• Abbott (Estados Unidos)
• F. Hoffmann-La Roche Ltd. (Suiza)
• Teva Pharmaceutical Industries Ltd. (Irlanda)
• Pfizer Inc. (Estados Unidos)
• GlaxoSmithKline plc (Reino Unido)
• WOCKHARDT (Bombay)
• Novo Nordisk A/S (Dinamarca)
• Glenmark Pharmaceuticals Limited (India)
• Cipla Inc. (Estados Unidos)
• Bausch Health Companies Inc. (Canadá)
• Otsuka America Pharmaceutical, Inc. (Estados Unidos)
• Johnson & Johnson Private Limited (Estados Unidos)
• Takeda Pharmaceutical Company Limited (Japón)
• Corporación Sumitomo (Japón)
• Biocon (India)

SKU-53290